Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

80 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Incidence and dynamics of Epstein-Barr virus reactivation after alemtuzumab-based conditioning for allogeneic hematopoietic stem-cell transplantation.
Carpenter B, Haque T, Dimopoulou M, Atkinson C, Roughton M, Grace S, Denovan S, Fielding A, Kottaridis PD, Griffiths P, Mackinnon S, Emery V, Chakraverty R. Carpenter B, et al. Among authors: kottaridis pd. Transplantation. 2010 Sep 15;90(5):564-70. doi: 10.1097/TP.0b013e3181e7a3bf. Transplantation. 2010. PMID: 20555307
Successful outcome following allogeneic hematopoietic stem cell transplantation in adults with primary immunodeficiency.
Fox TA, Chakraverty R, Burns S, Carpenter B, Thomson K, Lowe D, Fielding A, Peggs K, Kottaridis P, Uttenthal B, Bigley V, Buckland M, Grandage V, Denovan S, Grace S, Dahlstrom J, Workman S, Symes A, Mackinnon S, Hough R, Morris E. Fox TA, et al. Blood. 2018 Feb 22;131(8):917-931. doi: 10.1182/blood-2017-09-807487. Epub 2017 Dec 26. Blood. 2018. PMID: 29279357 Free PMC article.
Comparative analysis of melphalan versus busulphan T-cell deplete conditioning using alemtuzumab in unrelated donor stem cell transplantation for acute myeloid leukaemia.
Sellar RS, Mehra V, Fox TA, Grigg A, Kulasekararaj A, Sarma A, de Lavallade H, McLornan D, Raj K, Mufti GJ, Pagliuca A, Mackinnon S, Chakraverty R, Fielding AK, Carpenter B, Kottaridis PD, Khwaja A, Peggs KS, Thomson KJ, Morris EC, Potter VT. Sellar RS, et al. Among authors: kottaridis pd. Br J Haematol. 2019 Oct;187(1):e20-e24. doi: 10.1111/bjh.16136. Epub 2019 Aug 8. Br J Haematol. 2019. PMID: 31396948 Free article. No abstract available.
Successful remission induction therapy with gilteritinib in a patient with de novo FLT3-mutated acute myeloid leukaemia and severe COVID-19.
Wilson AJ, Troy-Barnes E, Subhan M, Clark F, Gupta R, Fielding AK, Kottaridis P, Mansour MR, O'Nions J, Payne E, Chavda N, Baker R, Thomson K, Khwaja A. Wilson AJ, et al. Br J Haematol. 2020 Aug;190(4):e189-e191. doi: 10.1111/bjh.16962. Epub 2020 Jul 19. Br J Haematol. 2020. PMID: 32584418 Free PMC article. No abstract available.
Concerns about how to use established minimal residual disease monitoring in the treatment of NPM1-mutant acute myeloid leukaemia (AML) following reduced intensity chemotherapy protocols for AML given as a result of the COVID-19 pandemic.
Farah N, Burt R, Ibrahim AR, Baker R, Kottaridis PD. Farah N, et al. Among authors: kottaridis pd. Br J Haematol. 2020 Aug;190(4):e208-e210. doi: 10.1111/bjh.16985. Epub 2020 Jul 26. Br J Haematol. 2020. PMID: 32609881 Free PMC article. No abstract available.
Predictors of recovery following allogeneic CD34+-selected cell infusion without conditioning to correct poor graft function.
Cuadrado MM, Szydlo RM, Watts M, Patel N, Renshaw H, Dorman J, Lowdell M, Ings S, Anthias C, Madrigal A, Mackinnon S, Kottaridis P, Carpenter B, Hough R, Morris E, Thomson K, Peggs KS, Chakraverty R. Cuadrado MM, et al. Haematologica. 2020 Nov 1;105(11):2639-2646. doi: 10.3324/haematol.2019.226340. Haematologica. 2020. PMID: 33131253 Free PMC article.
A randomised evaluation of low-dose cytosine arabinoside (ara-C) plus tosedostat versus low-dose ara-C in older patients with acute myeloid leukaemia: results of the LI-1 trial.
Dennis M, Burnett A, Hills R, Thomas I, Ariti C, Severinsen MT, Hemmaway C, Greaves P, Clark RE, Copland M, Russell N; National Cancer Research Institute (NCRI) acute myeloid leukaemia (AML) Working Group. Dennis M, et al. Br J Haematol. 2021 Jul;194(2):298-308. doi: 10.1111/bjh.17501. Epub 2021 May 7. Br J Haematol. 2021. PMID: 33961292 Clinical Trial.
Gilteritinib monotherapy as a transplant bridging option for high risk FLT3-mutated AML with t(6;9)(p23;q34.1);DEK-NUP214 in morphological but not cytogenetic or molecular remission following standard induction chemotherapy.
Day JW, Fox TA, Gupta R, Khwaja A, Wilson AJ, Kottaridis PD. Day JW, et al. Among authors: kottaridis pd. Leuk Res Rep. 2022 Feb 7;17:100291. doi: 10.1016/j.lrr.2022.100291. eCollection 2022. Leuk Res Rep. 2022. PMID: 35198371 Free PMC article.
80 results